Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for PQR309

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug PQR309?

PQR309 is an investigational drug.

There have been 9 clinical trials for PQR309. The most recent clinical trial was a Phase 1 trial, which was initiated on June 15th 2017.

The most common disease conditions in clinical trials are Lymphoma, Breast Neoplasms, and Lymphoma, Non-Hodgkin. The leading clinical trial sponsors are PIQUR Therapeutics AG, University Hospital, Basel, Switzerland, and Roswell Park Cancer Institute.

There are three US patents protecting this investigational drug and forty-four international patents.

Recent Clinical Trials for PQR309
Study Evaluating Safety and Efficacy of Bimiralisib in Patients With Head and Neck Squameous Cell CarcinomaPIQUR Therapeutics AGPhase 2
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaPIQUR Therapeutics AGPhase 2
Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma PatientsCharite University, Berlin, GermanyPhase 2

See all PQR309 clinical trials

Clinical Trial Summary for PQR309

Top disease conditions for PQR309
Top clinical trial sponsors for PQR309

See all PQR309 clinical trials

US Patents for PQR309

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PQR309   Start Trial Manufacturing process for triazine, pyrimidine and pyridine derivatives UNIVERSITAET BASEL (Basel, CH) PIQUR THERAPEUTICS AG (Basel, CH)   Start Trial
PQR309   Start Trial Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes University of Basel (Basel, CH)   Start Trial
PQR309   Start Trial Triazine compounds Sphaera Pharma PTE. Ltd. (Singapore, SG)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PQR309

Drugname Country Document Number Estimated Expiration Related US Patent
PQR309 Australia 2015250994 2034-04-22   Start Trial
PQR309 Brazil 112016023811 2034-04-22   Start Trial
PQR309 Canada 2944697 2034-04-22   Start Trial
PQR309 China 106458968 2034-04-22   Start Trial
PQR309 European Patent Office 3134388 2034-04-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.